About us

Our customers have always known that they can depend on MSD Animal Health for more than just medicines. They count on MSD Animal Health for information, technologies and veterinary services that truly advance animal healthcare. It is our heritage and our mission.

The Science of Healthier Animals

Today, our science supports the precious bond between people and their pets. It also helps protect international public health, ensure food safety and increase protein supplies.

Our core values

Today, our science supports the precious bond between people and their pets. It also helps protect international public health, ensure food safety and increase protein supplies.

RESPONSIBLE

Appreciating the fundamental role of progressive science in animal health, understanding the deep responsibility MSD Animal Health has to our customers, consumers, animals, society and the planet.

VISIONARY

Being original in thought and approach, having the confidence and determination to come up and work with new insights, greater understanding and fresh knowledge.

COLLABORATIVE

Working closely, sharing understanding and inspiring one another and customers, allowing science and thinking to flourish, enabling the right balance of cost against human capability.

DYNAMIC

Aiming at being efficient, fast and flexible in all operations, responding rapidly to new opportunities and demands, an outward orientated performance culture that values talent and action.

Our People

Bringing our purpose to life.

People don’t recognize all that goes into that little vial of well-being…there is so much care and technology behind making our products.”   

Pam Stoops, Executive Director, Plant Management, U.S. Manufacturing

Our culture is very much about people first and our company not only talks the talk, but also walks the walk.”

Gin Tafolla, Associate Director, Learning & Development, U.S. Livestock Team

It’s incredibly fulfilling to know that you can influence the lives of animals and humans alike.”   

Nikos Linardos, managing director, Greece & Cyprus.

I Am Animal Health is a series of stories about our people

A Legacy of Innovation

MSD Animal Health has a rich heritage of scientific excellence and innovation. It is the foundation of our future and the inspiration for our daily work.

2021

  • MSD Animal Health announces WHISPER® ON ARRIVAL, first-of-it-kind technology using a sound collection device and a predictive algorithm, that predicts which animals will benefit from treatment for the control of Bovine Respiratory Disease (BRD). 

  • MSD Animal Health expands its SEQUIVITY® veterinary prescription vaccine platform for sapovirus, an emerging virus causing diarrhea in young pigs.

    • MSD Animal Health launches FELAQUA® CONNECT, a water delivery and drinking monitoring system. Cat owners can track daily water intake via the SURE PETCARE™ App, while the smart water delivery system provides cats with fresh water.     

    • MSD Animal Health announces EXZOLT® as the first veterinary product centrally registered in the European Union to include animal welfare improvement in its Summary of Product Characteristics following a CVMP positive opinion in the European Union.  

    2020

    • MSD Animal Health receives CVMP positive opinion for INNOVAX®-ND-ILT in the European Union for protection against Marek’s Disease, Infectious Laryngotracheitis and Newcastle Disease

    • MSD Animal Health receives approval from the European Commission of  NOBIVAC® Respira Bb, an injectable Bordetella vaccine for dogs.

    • MSD Animal Health receives approval from the European Commission of  NOBILIS® SALENVAC® ETC, an inactivated trivalent Salmonella vaccine for poultry.

    • MSD Animal Health introduces the INNOJECT Pro, a subcutaneous chick vaccination technology for increased accuracy of injection and greater sustainability during the vaccination process, reducing stress to chicks.

    • MSD Animal Health receives a conditional license approval for gilvetmab, a caninized monoclonal antibody for treatment of dogs with mast cell tumors or melanomas, from the U.S. Department of Agriculture Center for Veterinary Biologics.

    • MSD Animal Health forms specialized operating unit, called MSD Animal Health Intelligence, to focus on animal health intelligence and data expertise.

    • MSD Animal Health acquires Quantified Ag, a data and analytics company that monitors cattle body temperature and movement in order to detect illness early.

    • MSD Animal Health acquires IdentiGEN, a leader in DNA-based  animal traceability solutions for Livestock and Aquaculture to accurately and precisely trace meat and poultry that is verifiable from fork-to-farm.

    • MSD Animal Health acquires U.S. rights to the SENTINEL® brand of combination parasiticides for Companion Animal, offering internal and external parasite protection.

    • MSD Animal Health receives U.S. Food and Drug Administration approval for  BRAVECTO® monthly chews for dogs and puppies 8 weeks of age and older for treatment and prevention of fleas and treatment and control of ticks.

      • MSD Animal Health receives U.S. Department of Agriculture approval for NASALGEN® 3, a three-way intranasal vaccine that protects beef and dairy cattle from the most common pneumonia-causing viral pathogens.

      • MSD Animal Health receives U.S. Food and Drug Administration approval for SHUTOUT™, an easy-to-administer teat sealant for the prevention of new intramammary infections throughout the dry period – the timeframe when cows are at the greatest risk.

      • MSD Animal Health announces results of a comprehensive study of wellbeing and mental health among U.S. veterinarians, which are critical issues facing the veterinary profession.

      • MSD Animal Health receives U.S. Food and Drug Administration approval for PORCILIS® Ileitis for multi-dose administration to vaccinate against ileitis caused by Lawsonia intracellularis.

      • MSD Animal Health announces $100 investment in facility expansion and enhancement efforts in its DeSoto, Kansas, manufacturing operations, including technological expansion of a vaccine production facility.

      • MSD Animal Health acquires worldwide rights to VECOXAN® brand of parasiticides to prevent coccidiosis for the Ruminant portfolio, available in Europe, South Africa, South Korea and Japan.

        2019

        • MSD Animal Health receives approval from the European Commission of  PORCILIS® Lawsonia intramuscular vaccine for piglets.

        • MSD Animal Health collaborates with Rapid Genomics for exclusive rights to a  vaccination verification tool, Viral Flex-Seq®, for use in combination with INNOVAX® vaccines, to optimize and enhance disease outbreak management in poultry.

        • MSD Animal Health acquires Allflex Livestock Intelligence, Sure Petcare and Biomark, as leaders in animal health digital tracking, traceability and monitoring technology for Livestock and Companion Animal.

        • MSD Animal Health acquires Vaki, a leader in fish farming and wild fish conservation monitoring equipment and real-time video monitoring technology to advance fish health and welfare.

        • MSD Animal Health acquires Scan Aqua AS, a fish health and fish welfare company in Norway.

        • MSD Animal Health signs a Memorandum of Understanding with Nanolek for establishment of a local vaccine manufacturing facility in Russia.

        • MSD Animal Health receives U.S. Food and Drug Administration approval for BRAVECTO® PLUS topical solution for cats, providing extended-duration, broad-spectrum coverage of internal and external parasites.

        2018

        • MSD Animal Health receives CVMP positive opinion for BRAVECTO® Plus spot-on solution for cats in the European Union for nose-to-toe parasite protection.

        • MSD Animal Health receives approval from the European Commission of an expanded indication of PANACUR® AquaSol to combat three gastrointestinal parasites in chickens. PANACUR AquaSol was originally approved in 2012 for the same indication in pigs to treat three similar types of parasites.

          • MSD Animal Health introduces the IDAL® 3G needle-free, intradermal swine vaccination device within their IDAL® way extended vaccine portfolio.

          • MSD Animal Health partners with Vinovo B.V. on novel delivery system to protect against highly infectious poultry diseases.

          • MSD Animal Health acquires animal vaccine company in China, including a manufacturing and R&D facility for expanded vaccine production.

            • MSD Animal Health introduces INNOVAX®-ND-IBD, the first live vaccine in the United States, made with biotechnology that protects against three highly infectious diseases in poultry – Newcastle Disease (ND), Infectious Bursal Disease (IBD) and Marek’s Disease (MD).

            • MSD Animal Health introduces its SEQUIVITY™ Technology, a highly innovative and highly advanced RNA Particle Technology used to create flexible, safe and precise vaccine solutions to new and evolving disease challenges.

            • MSD Animal Health announces the results of a large, well-controlled study with veterinarians designed to definitively quantify the prevalence of mental illness and stress in the veterinary profession and compare the findings to previous studies and the general U.S. population.

            2017

            • MSD Animal Health acquires Prondil S.A., a privately held company in Uruguay specializing in development and manufacturing of animal health vaccines for livestock.

            • MSD Animal Health acquires Vilsan Pharmaceuticals, a privately held producer of animal health products in Turkey, notably for ruminants.

            • MSD Animal Health acquires Vallée, a privately held producer of animal health products in Brazil.

            • MSD Animal Health announces its Whisper Veterinary Stethoscope System, a tool specifically designed to evaluate lung disease severity for more accurate diagnosis of Bovine Respiratory Disease (BRD).

            2016

            • MSD Animal Health receives U.S. Food and Drug Administration approval and CVMP positive opinion for BRAVECTO® for both cats and dogs in the European Union, up to 12 weeks of treatment and prevention of fleas and ticks.

            • Merck Animal Health becomes the first company to receive U.S. Department of Agriculture approval for NOBIVAC® Canine Influenza H3N2 Vaccine (CIV) to protect dogs against the newly identified strain of CIV.

            • Publication of the 11th edition of The Merck Veterinary Manual, a comprehensive reference that covers the diversity of species and animal diseases worldwide. Here you can access the MSD Veterinary Manual.    

            2015

            • MSD Animal Health receives a conditional product license from U.S. Department of Agriculture for NOBIVAC® Canine Influenza H3N2 Vaccine (CIV).

            • MSD Animal Health acquires Harrisvaccines, a privately held company that develops, manufactures and sells vaccines for food production and companion animal.

            2014

            • MSD Animal Health receives U.S. Food and Drug Administration approval of BRAVECTO®, the first chewable tablet for dogs for up to 12 weeks of treatment and prevention of fleas and ticks.

            • MSD Animal Health receives approval of PORCILIS® PCV M Hyo vaccine, Europe’s first single-shot vaccine to protect piglets from Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae infections.

            2011

            • The operating name of the animal health unit changes to MSD Animal Health.

            2009

            • Development of SPHEREON® freeze-drying technology for vaccines (Intervet/Schering-Plough Animal Health).

            • MSD acquires Schering-Plough. Intervet/Schering-Plough Animal Health becomes the animal health division of MSD, including HomeAgain®, a leader in microchip and pet recovery services.

            2007

            • Schering-Plough acquires Organon Biosciences (Intervet and Organon) from AKZO NOBEL. The animal health division operates as Intervet/Schering-Plough Animal Health.

            2005

            • Harrisvaccines was founded in Iowa (United States).

            2000s

            • Launch of SLICE® fish antiparasitic for the treatment of sea lice in salmon (Schering-Plough Animal Health).

            • Licensure of the first live bacterial recombinant vaccine against strangles in horses in the EU (Intervet).

            • Introduction of PORCILIS® Pesti, the first marker vaccine for classical swine fever (Intervet).

            1997

            • MSD and French pharmaceutical company Rhone-Merieux (later Sanofi) combine their animal health divisions in an equally owned joint venture named Merial.

            1990s

            • Development of florfenicol, a novel phenicol antibiotic exclusive to animal health (Schering-Plough Animal Health).

            • Introduction of antiparasitic SCALIBOR®, a dog collar to prevent Leishmaniasis from sand fly bites (Intervet).

            1980s

            • Development of first recombinant DNA vaccine (PORCILIS® Porcoli against diarrhea in piglets) by Intervet.

            1970s

            • Introduction of anti-inflammatory drug for horses (Schering-Plough Animal Health).

            • Intervet develops anthelmintic fenbendazole, which is still used today against parasites, such as roundworms and hookworms, that are found in the gastrointestinal and respiratory tracts of chickens.

            • Intervet launches products for reproduction management in farm animals.

            1961

            • Netherlands-based “Koninklijke Zwanenburg Organon” (which later became AKZO NOBEL) acquires Intervet.

            1955

            • Publication of first edition of The MSD Veterinary Manual.

            1950s

            • Schering-Plough Animal Health is established and comes to market with prednisone to treat ketosis in dairy cattle.

            • Intervet develops first fowl pox vaccine for poultry.

            1949

            • Feed manufacturer Wim Hendrix lays the foundation for Intervet in Boxmeer, The Netherlands, where the Animal Health headquarters of todays’ company remained until 2012.

            1940s

            • MSD establishes an Animal Health division and discovers sulfaquinoxaline, the first poultry coccidiostat.

              Photo source: MSD Archives, 2021.
              © 1955 Merck & Co., Inc., Kenilworth, NJ USA. and its affiliates. All rights reserved.

            Our Operations

            We operate in more than 150 countries.

            We’ve achieved our reach through an absolute commitment to regional understanding. It helps us react quickly to changing disease landscapes around the world. We help protect public health and effectively address local concerns.

            Featured Stories

            Explore our archive of featured stories and learn more about how MSD Animal Health protects the health of animals.